𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dementia and treatment with L-dopa in Parkinson's disease

✍ Scribed by M. Hietanen; Dr. H. Teräväinen

Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
536 KB
Volume
3
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

We compared the neuropsychological performance of patients with Parkinson's disease who were young at onset of the disease (mean age, 41.4 years) and had received prolonged L-dopa treatment (mean, 52.1 months) with nontreated patients of the same age. A similar comparison was made for patients who were older at onset of the disease (mean, 62.1 years). There were no significant differences in cognitive and memory functions between the L-Dopa-treated and untreated young patients, whereas the L-Dopa-treated patients in the older age group performed more poorly than untreated patients in some memory tests (Wechsler Memory Scale I: logical and visual) and cognitive functions (Wechsler Adult Intelligence Scale: similarities, block design, and cognitive flexibility). Treatment duration, disease duration, and mean L-Dopa dose were comparable for the two age groups. After linear effects of age and disease duration had been eliminated, the duration of r-Dopa treatment did not correlate with the cognitive variables studied. These observations suggest that treatment with L-Dopa may not be the cause of cognitive impairment in Parkinson's disease.

📜 SIMILAR VOLUMES

Treatment of dementia with Lewy bodies a
Treatment of dementia with Lewy bodies and Parkinson's disease dementia
✍ Werner Poewe 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD-dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological

Current treatment of dementia with Lewy
Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease
✍ David J. Burn; Ian G. McKeith 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Dementia in Parkinson's disease (PDD) is a frequent and distressing complication with major consequences. Clinical and pathological features closely link PDD and dementia with Lewy bodies (DLB), suggesting they represent part of the same disease spectrum. Although dopaminergic deficiency primarily d

Focusing effects of L-dopa in Parkinson'
Focusing effects of L-dopa in Parkinson's disease
✍ Bernard Ng; Samantha Palmer; Rafeef Abugharbieh; Martin J. McKeown 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 397 KB

## Abstract Previous fMRI motor studies in Parkinson's disease (PD) have suggested that L‐dopa may “normalize” areas of hypo‐ and hyperactivity. However, results from these studies, which were largely based on analyzing BOLD signal amplitude, have been conflicting. Examining only amplitude changes